

Minjie Wei

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2588338/publications.pdf>

Version: 2024-02-01

29
papers

4,704
citations

361296

20
h-index

454834

30
g-index

31
all docs

31
docs citations

31
times ranked

5297
citing authors

#	ARTICLE	IF	CITATIONS
1	A novel HIF-2 α targeted inhibitor suppresses hypoxia-induced breast cancer stemness via SOD2-mtROS-PDI/GPR78-UPRER axis. <i>Cell Death and Differentiation</i> , 2022, 29, 1769-1789.	5.0	30
2	LncRNA CBR3-AS1 regulates of breast cancer drug sensitivity as a competing endogenous RNA through the JNK1/MEK4-mediated MAPK signal pathway. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 41.	3.5	30
3	LncRNA-Xist/miR-101-3p/KLF6/C/EBP β axis promotes TAM polarization to regulate cancer cell proliferation and migration. <i>Molecular Therapy - Nucleic Acids</i> , 2021, 23, 536-551.	2.3	80
4	Integrated microenvironment-associated genomic profiles identify LRRC15 mediating recurrent glioblastoma-associated macrophages infiltration. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 5534-5546.	1.6	7
5	NF- κ B-activated SPRY4-IT1 promotes cancer cell metastasis by downregulating TCEB1 mRNA via Staufen1-mediated mRNA decay. <i>Oncogene</i> , 2021, 40, 4919-4929.	2.6	15
6	N6-methyladenosine reader IMP2 stabilizes the ZFAS1/OLA1 axis and activates the Warburg effect: implication in colorectal cancer. <i>Journal of Hematology and Oncology</i> , 2021, 14, 188.	6.9	55
7	Immune-Related Long Non-coding RNA Constructs a Prognostic Signature of Ovarian Cancer. <i>Biological Procedures Online</i> , 2021, 23, 24.	1.4	5
8	Bioinformatic profiling identifies a platinum-resistant-related risk signature for ovarian cancer. <i>Cancer Medicine</i> , 2020, 9, 1242-1253.	1.3	8
9	LncRNA SPRY4-IT1 regulates breast cancer cell stemness through competitively binding miR-6882-3p with TCF7L2. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 772-784.	1.6	50
10	Development of an IFN γ response-related signature for predicting the survival of cutaneous melanoma. <i>Cancer Medicine</i> , 2020, 9, 8186-8201.	1.3	17
11	Integrative Analysis of DNA Methylation and Gene Expression to Determine Specific Diagnostic Biomarkers and Prognostic Biomarkers of Breast Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 529386.	1.8	18
12	Analysis of immune subtypes based on immunogenomic profiling identifies prognostic signature for cutaneous melanoma. <i>International Immunopharmacology</i> , 2020, 89, 107162.	1.7	12
13	LNC942 promoting METTL14-mediated m6A methylation in breast cancer cell proliferation and progression. <i>Oncogene</i> , 2020, 39, 5358-5372.	2.6	131
14	Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion. <i>Cancer Cell</i> , 2020, 38, 79-96.e11.	7.7	389
15	Expression signature of six snoRNA serves as novel non-invasive biomarker for diagnosis and prognosis prediction of renal clear cell carcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 2215-2228.	1.6	32
16	LncRNA HOTTIP facilitates the stemness of breast cancer via regulation of miR-148a-3p/WNT1 pathway. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 6242-6252.	1.6	42
17	A five-mRNA signature associated with post-translational modifications can better predict recurrence and survival in cervical cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 6283-6297.	1.6	15
18	Long noncoding RNA ZFAS1 promoting small nucleolar RNA-mediated 2-O-methylation via NOP58 recruitment in colorectal cancer. <i>Molecular Cancer</i> , 2020, 19, 95.	7.9	73

#	ARTICLE	IF	CITATIONS
19	Long non-coding RNA LUCAT1/miR-5582-3p/TCF7L2 axis regulates breast cancer stemness via Wnt/ β 2-catenin pathway. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 305.	3.5	107
20	Intrinsic adriamycin resistance in p53-mutated breast cancer is related to the miR-30c/FANCF/REV1-mediated DNA damage response. <i>Cell Death and Disease</i> , 2019, 10, 666.	2.7	19
21	Hypoxia-inducible factor-2 directly promotes BCRP expression and mediates the resistance of ovarian cancer stem cells to adriamycin. <i>Molecular Oncology</i> , 2019, 13, 403-421.	2.1	47
22	Recognition of RNA N6-methyladenosine by IGF2BP proteins enhances mRNA stability and translation. <i>Nature Cell Biology</i> , 2018, 20, 285-295.	4.6	1,650
23	METTL14 Inhibits Hematopoietic Stem/Progenitor Differentiation and Promotes Leukemogenesis via mRNA m6A Modification. <i>Cell Stem Cell</i> , 2018, 22, 191-205.e9.	5.2	749
24	R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m6A/MYC/CEBPA Signaling. <i>Cell</i> , 2018, 172, 90-105.e23.	13.5	794
25	High PITX1 expression in lung adenocarcinoma patients is associated with DNA methylation and poor prognosis. <i>Pathology Research and Practice</i> , 2018, 214, 2046-2053.	1.0	24
26	HIF-2 promotes conversion to a stem cell phenotype and induces chemoresistance in breast cancer cells by activating Wnt and Notch pathways. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 256.	3.5	124
27	miR-302a/b/c/d cooperatively inhibit BCRP expression to increase drug sensitivity in breast cancer cells. <i>Gynecologic Oncology</i> , 2016, 141, 592-601.	0.6	51
28	MiR-302a/b/c/d cooperatively sensitizes breast cancer cells to adriamycin via suppressing P-glycoprotein(P-gp) by targeting MAP/ERK kinase kinase 1 (MEKK1). <i>Journal of Experimental and Clinical Cancer Research</i> , 2016, 35, 25.	3.5	82
29	The Hedgehog signalling pathway mediates drug response of MCF-7 mammosphere cells in breast cancer patients. <i>Clinical Science</i> , 2015, 129, 809-822.	1.8	46